http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 17 Jun 2026 16:33:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Travere+Therapeutics%2C++++++++++++++++/26660460.html si-local-file:///var/storage/secattach/20260617/26660460.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Travere+Therapeutics%2C++++++++++++++++/26660460.html Wed, 17 Jun 2026 16:33:00 -0400 O.09235062 TVTX http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Travere+Therapeutics%2C++++++++++++++++/26660460.html si-local-file:///var/storage/secattach/20260617/26660460.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Travere+Therapeutics%2C++++++++++++++++/26660460.html Wed, 17 Jun 2026 16:33:00 -0400 O.09235062 TVTX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Travere+Therapeutics%2C+++++For%3A+Jun+12++Filed+by%3A+Coughlin+Timothy/26654859.html si-local-file:///var/storage/secattach/20260616/26654859.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Travere+Therapeutics%2C+++++For%3A+Jun+12++Filed+by%3A+Coughlin+Timothy/26654859.html Tue, 16 Jun 2026 16:47:00 -0400 O.09235062 TVTX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Travere+Therapeutics%2C+++++For%3A+Jun+12++Filed+by%3A+Coughlin+Timothy/26654859.html si-local-file:///var/storage/secattach/20260616/26654859.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Travere+Therapeutics%2C+++++For%3A+Jun+12++Filed+by%3A+Coughlin+Timothy/26654859.html Tue, 16 Jun 2026 16:47:00 -0400 O.09235062 TVTX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Travere+Therapeutics%2C+++++For%3A+Jun+12++Filed+by%3A+Baynes+Roy+D./26654787.html si-local-file:///var/storage/secattach/20260616/26654787.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Travere+Therapeutics%2C+++++For%3A+Jun+12++Filed+by%3A+Baynes+Roy+D./26654787.html Tue, 16 Jun 2026 16:43:00 -0400 O.09235062 TVTX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Travere+Therapeutics%2C+++++For%3A+Jun+12++Filed+by%3A+Baynes+Roy+D./26654787.html si-local-file:///var/storage/secattach/20260616/26654787.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Travere+Therapeutics%2C+++++For%3A+Jun+12++Filed+by%3A+Baynes+Roy+D./26654787.html Tue, 16 Jun 2026 16:43:00 -0400 O.09235062 TVTX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Travere+Therapeutics%2C+++++For%3A+Jun+12/26654628.html si-local-file:///var/storage/secattach/20260616/26654628.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Travere+Therapeutics%2C+++++For%3A+Jun+12/26654628.html Tue, 16 Jun 2026 16:35:00 -0400 O.09235062 TVTX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Travere+Therapeutics%2C+++++For%3A+Jun+12/26654628.html si-local-file:///var/storage/secattach/20260616/26654628.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Travere+Therapeutics%2C+++++For%3A+Jun+12/26654628.html Tue, 16 Jun 2026 16:35:00 -0400 O.09235062 TVTX http://www.streetinsider.com/Corporate+News/Travere+Therapeutics+names+new+R%26D+head+ahead+of+2027+retirement/26654512.html <p>Travere Therapeutics (Nasdaq: TVTX) announced that William Rote, Ph.D., its chief research officer, plans to retire in February 2027 after 10 years with the company.</p><p>Jula Inrig, M.D., currently chief medical officer, will expand her responsibilities to lead both research and development functions. She will be named executive vice president, head of research and development and CMO, adding oversight of regulatory affairs, quality, technical operations, biometrics and research to her existing duties.</p><p>Dr. Inrig joined Travere in January 2022. Before that, she served as global head of the Renal Center of Excellence at IQVIA. She has more than 20 years of experience http://www.streetinsider.com/Corporate+News/Travere+Therapeutics+names+new+R%26D+head+ahead+of+2027+retirement/26654512.html Tue, 16 Jun 2026 16:30:51 -0400 TVTX http://www.streetinsider.com/Management+Changes/Travere+Therapeutics+names+new+R%26D+head+ahead+of+2027+retirement/26654512.html <p>Travere Therapeutics (Nasdaq: TVTX) announced that William Rote, Ph.D., its chief research officer, plans to retire in February 2027 after 10 years with the company.</p><p>Jula Inrig, M.D., currently chief medical officer, will expand her responsibilities to lead both research and development functions. She will be named executive vice president, head of research and development and CMO, adding oversight of regulatory affairs, quality, technical operations, biometrics and research to her existing duties.</p><p>Dr. Inrig joined Travere in January 2022. Before that, she served as global head of the Renal Center of Excellence at IQVIA. She has more than 20 years of experience http://www.streetinsider.com/Management+Changes/Travere+Therapeutics+names+new+R%26D+head+ahead+of+2027+retirement/26654512.html Tue, 16 Jun 2026 16:30:51 -0400 TVTX http://www.streetinsider.com/Press+Releases/Travere+Therapeutics+Announces+Planned+Retirement+of+Chief+Research+Officer+in+2027/26654490.html <p class="bwalignc"> <i>William Rote, Ph.D., chief research officer plans to retire in early 2027</i> </p><p class="bwalignc"> <i>Jula Inrig, M.D., to be named executive vice president, head of research and development and CMO, expanding her responsibilities to include the Company’s research organization</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that William Rote, Ph.D., the Company’s chief research officer, plans to retire from the Company in February 2027 following 10 years of service. Jula Inrig, M.D., currently chief medical officer and a member of the Company’s executive leadership team, will expand her responsibilities to include the Company’s research organization and http://www.streetinsider.com/Press+Releases/Travere+Therapeutics+Announces+Planned+Retirement+of+Chief+Research+Officer+in+2027/26654490.html Tue, 16 Jun 2026 16:30:00 -0400 A.50200193 O.00448140 O.09235062 TVTX http://www.streetinsider.com/Press+Releases/Travere+Therapeutics+Announces+Planned+Retirement+of+Chief+Research+Officer+in+2027/26654490.html <p class="bwalignc"> <i>William Rote, Ph.D., chief research officer plans to retire in early 2027</i> </p><p class="bwalignc"> <i>Jula Inrig, M.D., to be named executive vice president, head of research and development and CMO, expanding her responsibilities to include the Company’s research organization</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that William Rote, Ph.D., the Company’s chief research officer, plans to retire from the Company in February 2027 following 10 years of service. Jula Inrig, M.D., currently chief medical officer and a member of the Company’s executive leadership team, will expand her responsibilities to include the Company’s research organization and http://www.streetinsider.com/Press+Releases/Travere+Therapeutics+Announces+Planned+Retirement+of+Chief+Research+Officer+in+2027/26654490.html Tue, 16 Jun 2026 16:30:00 -0400 A.50200193 O.00448140 O.09235062 TVTX http://www.streetinsider.com/Press+Releases/Travere+Therapeutics+Announces+Planned+Retirement+of+Chief+Research+Officer+in+2027/26654490.html <p class="bwalignc"> <i>William Rote, Ph.D., chief research officer plans to retire in early 2027</i> </p><p class="bwalignc"> <i>Jula Inrig, M.D., to be named executive vice president, head of research and development and CMO, expanding her responsibilities to include the Company’s research organization</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that William Rote, Ph.D., the Company’s chief research officer, plans to retire from the Company in February 2027 following 10 years of service. Jula Inrig, M.D., currently chief medical officer and a member of the Company’s executive leadership team, will expand her responsibilities to include the Company’s research organization and http://www.streetinsider.com/Press+Releases/Travere+Therapeutics+Announces+Planned+Retirement+of+Chief+Research+Officer+in+2027/26654490.html Tue, 16 Jun 2026 16:30:00 -0400 A.50200193 O.00448140 O.09235062 TVTX http://www.streetinsider.com/Press+Releases/Travere+Therapeutics+Announces+Planned+Retirement+of+Chief+Research+Officer+in+2027/26654490.html <p class="bwalignc"> <i>William Rote, Ph.D., chief research officer plans to retire in early 2027</i> </p><p class="bwalignc"> <i>Jula Inrig, M.D., to be named executive vice president, head of research and development and CMO, expanding her responsibilities to include the Company’s research organization</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that William Rote, Ph.D., the Company’s chief research officer, plans to retire from the Company in February 2027 following 10 years of service. Jula Inrig, M.D., currently chief medical officer and a member of the Company’s executive leadership team, will expand her responsibilities to include the Company’s research organization and http://www.streetinsider.com/Press+Releases/Travere+Therapeutics+Announces+Planned+Retirement+of+Chief+Research+Officer+in+2027/26654490.html Tue, 16 Jun 2026 16:30:00 -0400 A.50200193 O.00448140 O.09235062 TVTX http://www.streetinsider.com/Business+Wire/Travere+Therapeutics+Announces+Planned+Retirement+of+Chief+Research+Officer+in+2027/26654490.html <p class="bwalignc"> <i>William Rote, Ph.D., chief research officer plans to retire in early 2027</i> </p><p class="bwalignc"> <i>Jula Inrig, M.D., to be named executive vice president, head of research and development and CMO, expanding her responsibilities to include the Company’s research organization</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that William Rote, Ph.D., the Company’s chief research officer, plans to retire from the Company in February 2027 following 10 years of service. Jula Inrig, M.D., currently chief medical officer and a member of the Company’s executive leadership team, will expand her responsibilities to include the Company’s research organization and http://www.streetinsider.com/Business+Wire/Travere+Therapeutics+Announces+Planned+Retirement+of+Chief+Research+Officer+in+2027/26654490.html Tue, 16 Jun 2026 16:30:00 -0400 A.50200193 O.00448140 O.09235062 TVTX http://www.streetinsider.com/Business+Wire/Travere+Therapeutics+Announces+Planned+Retirement+of+Chief+Research+Officer+in+2027/26654490.html <p class="bwalignc"> <i>William Rote, Ph.D., chief research officer plans to retire in early 2027</i> </p><p class="bwalignc"> <i>Jula Inrig, M.D., to be named executive vice president, head of research and development and CMO, expanding her responsibilities to include the Company’s research organization</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that William Rote, Ph.D., the Company’s chief research officer, plans to retire from the Company in February 2027 following 10 years of service. Jula Inrig, M.D., currently chief medical officer and a member of the Company’s executive leadership team, will expand her responsibilities to include the Company’s research organization and http://www.streetinsider.com/Business+Wire/Travere+Therapeutics+Announces+Planned+Retirement+of+Chief+Research+Officer+in+2027/26654490.html Tue, 16 Jun 2026 16:30:00 -0400 A.50200193 O.00448140 O.09235062 TVTX http://www.streetinsider.com/Business+Wire/Travere+Therapeutics+Announces+Planned+Retirement+of+Chief+Research+Officer+in+2027/26654490.html <p class="bwalignc"> <i>William Rote, Ph.D., chief research officer plans to retire in early 2027</i> </p><p class="bwalignc"> <i>Jula Inrig, M.D., to be named executive vice president, head of research and development and CMO, expanding her responsibilities to include the Company’s research organization</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that William Rote, Ph.D., the Company’s chief research officer, plans to retire from the Company in February 2027 following 10 years of service. Jula Inrig, M.D., currently chief medical officer and a member of the Company’s executive leadership team, will expand her responsibilities to include the Company’s research organization and http://www.streetinsider.com/Business+Wire/Travere+Therapeutics+Announces+Planned+Retirement+of+Chief+Research+Officer+in+2027/26654490.html Tue, 16 Jun 2026 16:30:00 -0400 A.50200193 O.00448140 O.09235062 TVTX http://www.streetinsider.com/Business+Wire/Travere+Therapeutics+Announces+Planned+Retirement+of+Chief+Research+Officer+in+2027/26654490.html <p class="bwalignc"> <i>William Rote, Ph.D., chief research officer plans to retire in early 2027</i> </p><p class="bwalignc"> <i>Jula Inrig, M.D., to be named executive vice president, head of research and development and CMO, expanding her responsibilities to include the Company’s research organization</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that William Rote, Ph.D., the Company’s chief research officer, plans to retire from the Company in February 2027 following 10 years of service. Jula Inrig, M.D., currently chief medical officer and a member of the Company’s executive leadership team, will expand her responsibilities to include the Company’s research organization and http://www.streetinsider.com/Business+Wire/Travere+Therapeutics+Announces+Planned+Retirement+of+Chief+Research+Officer+in+2027/26654490.html Tue, 16 Jun 2026 16:30:00 -0400 A.50200193 O.00448140 O.09235062 TVTX http://www.streetinsider.com/Analyst+PT+Change/Travere+Therapeutics+%28TVTX%29+PT+Raised+to+%2470+at+Citi/26643410.html <p>Citi analyst Yigal Nochomovitz raised the price target on Travere Therapeutics (NASDAQ: TVTX) to $70.00 (from $62.00) while maintaining a Buy rating.</p> http://www.streetinsider.com/Analyst+PT+Change/Travere+Therapeutics+%28TVTX%29+PT+Raised+to+%2470+at+Citi/26643410.html Mon, 15 Jun 2026 05:35:56 -0400 TVTX http://www.streetinsider.com/SEC+Filings/Form++144++++++++Travere+Therapeutics%2C++++++++++++++++++Filed+by%3A+Baynes+Roy+D./26640627.html si-local-file:///var/storage/secattach/20260612/26640627.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Travere+Therapeutics%2C++++++++++++++++++Filed+by%3A+Baynes+Roy+D./26640627.html Fri, 12 Jun 2026 16:05:00 -0400 O.09235062 TVTX http://www.streetinsider.com/SEC+Filings/Form++144++++++++Travere+Therapeutics%2C++++++++++++++++++Filed+by%3A+Baynes+Roy+D./26640627.html si-local-file:///var/storage/secattach/20260612/26640627.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Travere+Therapeutics%2C++++++++++++++++++Filed+by%3A+Baynes+Roy+D./26640627.html Fri, 12 Jun 2026 16:05:00 -0400 O.09235062 TVTX http://www.streetinsider.com/SEC+Filings/Form++144++++++++Travere+Therapeutics%2C++++++++++++++++++Filed+by%3A+Coughlin+Timothy/26639637.html si-local-file:///var/storage/secattach/20260612/26639637.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Travere+Therapeutics%2C++++++++++++++++++Filed+by%3A+Coughlin+Timothy/26639637.html Fri, 12 Jun 2026 12:20:00 -0400 O.09235062 TVTX http://www.streetinsider.com/SEC+Filings/Form++144++++++++Travere+Therapeutics%2C++++++++++++++++++Filed+by%3A+Coughlin+Timothy/26639637.html si-local-file:///var/storage/secattach/20260612/26639637.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Travere+Therapeutics%2C++++++++++++++++++Filed+by%3A+Coughlin+Timothy/26639637.html Fri, 12 Jun 2026 12:20:00 -0400 O.09235062 TVTX http://www.streetinsider.com/Analyst+PT+Change/Travere+Therapeutics+%28TVTX%29+PT+Raised+to+%2465+at+Wells+Fargo/26638023.html Wells Fargo analyst Mohit Bansal raised the price target on Travere Therapeutics (NASDAQ: TVTX) to $65.00 (from $50.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Travere+Therapeutics+%28TVTX%29+PT+Raised+to+%2465+at+Wells+Fargo/26638023.html Fri, 12 Jun 2026 06:33:48 -0400 TVTX http://www.streetinsider.com/Press+Releases/Travere+Therapeutics+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26636594.html <p> SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on June 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 32,000 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4). </p><p> The RSUs vest http://www.streetinsider.com/Press+Releases/Travere+Therapeutics+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26636594.html Thu, 11 Jun 2026 17:00:00 -0400 O.09235062 TVTX